Epigral consolidated net profit rises 12.45% in the March 2025 quarter
05 - May - 2025 12:00 | 29 days ago
Net profit of Epigral rose 12.45% to Rs 86.89 crore in the quarter ended March 2025 as against Rs 77.27 crore during the previous quarter ended March 2024. Sales rose 19.63% to Rs 627.63 crore in the quarter ended March 2025 as against Rs 524.63 crore during the previous quarter ended March 2024.
For the full year,net profit rose 82.62% to Rs 357.69 crore in the year ended March 2025 as against Rs 195.87 crore during the previous year ended March 2024. Sales rose 32.19% to Rs 2550.13 crore in the year ended March 2025 as against Rs 1929.19 crore during the previous year ended March 2024.
Epigral announced that the Board of Directors of the Company at its meeting held on 5 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.
Epigral consolidated net profit rises 12.45% in the March 2025 quarter
05 - May - 2025 12:00 | 29 days ago
Net profit of Epigral rose 12.45% to Rs 86.89 crore in the quarter ended March 2025 as against Rs 77.27 crore during the previous quarter ended March 2024. Sales rose 19.63% to Rs 627.63 crore in the quarter ended March 2025 as against Rs 524.63 crore during the previous quarter ended March 2024.
For the full year,net profit rose 82.62% to Rs 357.69 crore in the year ended March 2025 as against Rs 195.87 crore during the previous year ended March 2024. Sales rose 32.19% to Rs 2550.13 crore in the year ended March 2025 as against Rs 1929.19 crore during the previous year ended March 2024.
Epigral announced that the Board of Directors of the Company at its meeting held on 5 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.
Epigral consolidated net profit rises 12.45% in the March 2025 quarter
05 - May - 2025 12:00 | 29 days ago
Net profit of Epigral rose 12.45% to Rs 86.89 crore in the quarter ended March 2025 as against Rs 77.27 crore during the previous quarter ended March 2024. Sales rose 19.63% to Rs 627.63 crore in the quarter ended March 2025 as against Rs 524.63 crore during the previous quarter ended March 2024.
For the full year,net profit rose 82.62% to Rs 357.69 crore in the year ended March 2025 as against Rs 195.87 crore during the previous year ended March 2024. Sales rose 32.19% to Rs 2550.13 crore in the year ended March 2025 as against Rs 1929.19 crore during the previous year ended March 2024.
Epigral announced that the Board of Directors of the Company at its meeting held on 5 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.
Epigral consolidated net profit rises 12.45% in the March 2025 quarter
05 - May - 2025 12:00 | 29 days ago
Net profit of Epigral rose 12.45% to Rs 86.89 crore in the quarter ended March 2025 as against Rs 77.27 crore during the previous quarter ended March 2024. Sales rose 19.63% to Rs 627.63 crore in the quarter ended March 2025 as against Rs 524.63 crore during the previous quarter ended March 2024.
For the full year,net profit rose 82.62% to Rs 357.69 crore in the year ended March 2025 as against Rs 195.87 crore during the previous year ended March 2024. Sales rose 32.19% to Rs 2550.13 crore in the year ended March 2025 as against Rs 1929.19 crore during the previous year ended March 2024.
Epigral announced that the Board of Directors of the Company at its meeting held on 5 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.
Epigral consolidated net profit rises 12.45% in the March 2025 quarter
05 - May - 2025 12:00 | 29 days ago
Net profit of Epigral rose 12.45% to Rs 86.89 crore in the quarter ended March 2025 as against Rs 77.27 crore during the previous quarter ended March 2024. Sales rose 19.63% to Rs 627.63 crore in the quarter ended March 2025 as against Rs 524.63 crore during the previous quarter ended March 2024.
For the full year,net profit rose 82.62% to Rs 357.69 crore in the year ended March 2025 as against Rs 195.87 crore during the previous year ended March 2024. Sales rose 32.19% to Rs 2550.13 crore in the year ended March 2025 as against Rs 1929.19 crore during the previous year ended March 2024.
Epigral announced that the Board of Directors of the Company at its meeting held on 5 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.
